Zoonotic & Vector-Borne Diseases

Ross M Boyce, MD, MSc, discusses the diagnostic challenges and the need for greater awareness of tick-borne illnesses in the US, considering their potential severity.

Sesh Sundararaman, MD, PhD, discusses his findings and how this approach can be triggered to minimize undesirable treatment features and open the door to newer treatment possibilities.

Amanda Truong, MD, PhD, provides her perspective on diagnosis, treatment, and environmental factors, considering her involvement in a recent human case.

The vaccine is based on an attenuated rabies vaccine that was subsequently inactivated to make the vaccine candidate. The National Institutes of Health (NIH) is sponsoring the trial.

The phase 1/2a trial of BioNTech's BNT165e vaccine, involving nearly 180 participants, faces delays as global malaria control efforts struggle with funding and political uncertainties.

Sunil Parikh, MD, MPH, discusses the trial’s findings, noting no significant difference in malaria incidence (1.78 vs 1.84 cases per 100 person-weeks).

Sunil Parikh, MD, MPH, discussed how challenges like drug resistance and the limitations of current methods hindered ivermectin’s effectiveness in reducing malaria incidence.

Approved vaccines for chikungunya, meningococcal disease, updates on HIV prevention, key regulatory decisions, and more.

Jeff Freiberg, MD, PhD, on the rising emerging infection concerns of dengue, mpox, measles, and H5N1 influenza in clinical practice.

The approval is based on positive phase 3 clinical trial results, offering an effective option for travelers and others at risk of chikungunya, the mosquito-borne illness.

Carlien Pohl-Albertyn's, PhD research highlights the role of the South African brown locust in the transmission and survival of the emerging pathogen Candida auris.

Researchers identify Camp Hill virus, a novel henipavirus in shrews, raising concerns about human exposure to emerging infectious diseases.

Oropouche fever, primarily found in Central and South America and the Caribbean, has seen a dramatic increase in cases in Brazil.

Caryn Fenner and Petro Terblanche outline Afrigen's clinical trial plans, local partnerships, and vaccine pipeline.

Caryn Fenner and Petro Terblanche explain how CEPI’s $6.2 million grant will advance Afrigen’s mRNA vaccine for Rift Valley fever through preclinical and Phase I trials in Africa.

These types of infections will continue to rise, and there is a need to understand what we are witnessing and find ways to combat them.

Rising temperatures and changing humidity are undermining natural pest control, putting North American forests at risk.

Over a third of respondents in 6 African countries were hesitant to get the vaccine themselves. And for parents, nearly 40% were reluctant to get their children immunized.

The largest blastomycosis outbreak linked to a paper mill in Michigan and a 56% increase in tularemia cases over the past decade.

Emerging data reveal surprising patterns in maternal–fetal outcomes linked to avian influenza virus infection.

143 deaths and 592 cases confirmed in Kwango Province, with concerns about treatment access, drug resistance, and more.

Health officials are investigating an outbreak called "Dinga Dinga," which causes fever and uncontrollable shaking.

Sexual transmission was confirmed for nine of the 22 viruses studied, including Ebola, Zika, and mpox, making it a key factor in ongoing disease spread.

Milad Zandi, PhD, on rising temperatures and the spread of mosquito-borne diseases like dengue, Zika, and chikungunya, increasing the risk of outbreaks in tropical and temperate regions.

This comes after Japan recently announced it will donate over 3 million doses of the mpox vaccine, LC16m8 to a country in Africa.